InteKrin Therapeutics, Inc.
InteKrin Therapeutics, Inc. (InteKrin) is a development stage biopharmaceutical company engaged in development and commercialization of innovative therapeutics for neuroendocrine, metabolic, and immune disorders. The company is actively pursuing development of treatments for insulin resistance, and obesity. The company develops INT131 as its lead product candidate for the treatment of Type 2 diabetes mellitus (T2DM) in phase II of clinical trials. INT131 is being developed as a non-TZD, selective peroxisome proliferator-activated receptor gamma modulator. The company is headquartered as Los Altos, California, the US.